From the self-watching self to the predicting brain, explore 12 neuroscience-backed perspectives on consciousness. Discover ...

The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Making a good digital picture frame should be easy. All you need is a good screen and an uncomplicated way to get your favorite photos onto the device. Combine that with an inoffensive, frame-like ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

I know what you're probably thinking – why put out a new VR headset in 2026? Big hit VR games have been few and far between in recent years, but Valve is convinced that there's still an appetite for ...

Valve has announced a brand new VR headset. It's called the Steam Frame, and it's set to launch next year. While pricing is not yet confirmed, I've been to Valve HQ to try it out and get all the ...

In recent developments, Recursion Pharmaceuticals unveiled advances in its AI platform for drug discovery, forming collaborations with major pharmaceutical groups including Sanofi, Roche/Genentech, ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...